Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep873 | Pituitary - Clinical | ECE2016

Comorbidities and treatment patterns among patients with acromegaly in Sweden : a register-linkage population-based study

Lesen Eva , Granfeldt Daniel , Houchard Aude , Dinet Jerome , Berthon Anthony , Bjorholt Ingela , Johannsson Gudmundur

Introduction: Treatment of patients with acromegaly is complex, including surgery, pharmacotherapy and radiotherapy. The objective was to describe comorbidities and treatment patterns among patients with acromegaly in Sweden.Methods: Population-based study including all patients with a first diagnosis of acromegaly due to a pituitary adenoma in Sweden between 1 Jul 2005 and 31 Dec 2013. Data was obtained via linkage of the National Patient Register, Swed...

ea0037gp.01.02 | Adrenal | ECE2015

Defining and exploring the excessive healthcare burden of adrenal insufficiency

Stewart Paul , Biller Beverly M K , Marelli Claudio , Gunnarsson Candace , Ryan Michael , Johannsson Gudmundur

Introduction: The clinical outcome of patients with adrenal insufficiency (AI) has been shown to be less favorable than previously thought. Clinical studies have shown increased mortality, reduced cardiovascular and skeletal health and compromised quality of life, but the impact of this upon healthcare burden is unknown. This research utilised real-world evidence to compare comorbidities, healthcare utilization and expenditures in patients with AI.Method...

ea0037gp.20.01 | Pituitary – Hypopituitarism | ECE2015

Reduced mortality due to malignant neoplasms in patients receiving long-term GH replacement therapy – a Swedish study based on more than 4000 patient-years

Olsson Daniel S , Nilsson Anna G , Trimpou Penelope , Bengtsson Bengt-AEke , Andersson Eva , Johannsson Gudmundur

Patients with hypopituitarism and untreated growth hormone (GH) deficiency have excess mortality. GH replacement therapy (GHRT) has many beneficial effects, but its impact on mortality has not been proven and there are still safety concerns regarding the potential cancer risk. We have therefore studied the mortality in non-functioning pituitary adenoma (NFPA) patients with and without GHRT. Only patients with NFPA were studied in order to eliminate the influence of the aetiolo...

ea0070aep676 | Pituitary and Neuroendocrinology | ECE2020

European Society of Endocrinology audit and multi-country comparison of Adult Growth Hormone Deficiency (AGHD) treatment in clinical practice in Europe and Australia; –how closely are protocols and best practice recommendations followed

Martel-Duguech Luciana , Screen Nik , Jorgensen Jens Otto L , Korbonits Marta , Johannsson Gudmundur , Webb Susan M

Background: Current guidelines recommend that susceptible patients should be tested and treated for AGHD. Still, it is not universally recognised as a distinct entity and reimbursement of GH replacement therapy is not available in some countries.Aim: 1) to record current practice of AGHD management throughout Europe and benchmark it against existing guidelines, 2) to evaluate educational status of health care professionals.Patients...

ea0032oc1.6 | Pituitary & Molecular Endocrinology | ECE2013

Management of euvolemic hyponatremia attributed to SIADH in the hospital: interim results from a prospective, observational, multi-center, global registry

Peri Alessandro , Verbalis Joseph , Greenberg Arthur , Johannsson Gudmundur , Ball Steven , Jorgensen Jens Otto , Chiodo Joseph

Introduction: Hyponatremia (HN) is the most common electrolyte disorder of hospitalized patients (pts). It occurs in up to 28% of in-pts, increases the in hospital risk of death by 1.47 fold, and is associated with significantly higher mortality risk following discharge. The HN Registry is the first large scale, international effort to document the clinical characteristics, treatments used, and impact of HN in hospital settings.Methods: After informed co...

ea0032p24 | Adrenal cortex | ECE2013

Management of Addison's disease patients using dual release hydrocortisone during periods of intercurrent illness

Simonsson Ulrika SH , Skrtic Stanko , Lennernas Hans , Marelli Claudio , Johannsson Gudmundur

Introduction: Current management of intercurrent illness (ICI) in adrenal insufficiency (AI) is inadequate. We attempted to optimise ICI regimens with pharmacokinetic simulations of a dual-release (DR) hydrocortisone (HC) and tested them in a formal clinical trial.Methods: This work consisted of: i) dosing recommendations in episodes of mild ICI with DR-HC using simulations with a population pharmacokinetic model, ii) collection of ICI episodes with incr...

ea0032p703 | Neuroendocrinology | ECE2013

Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome

Ragnarsson Oskar , Berglund Peter , Eder Detek N , Zetterberg Henrik , Hietala Max A , Blennow Kaj , Johannsson Gudmundur

Background: Patients with Cushing’s syndrome (CS) in long-term remission have impaired cognitive function. Cerebrospinal fluid (CSF) biomarkers are important diagnostic tools in the work-up of patients with cognitive impairment. The aim of this study was to analyze biological markers in CSF from patients with CS in remission. Owing to the overlapping similarities between patients with CS and dementia, i.e. cognitive dysfunction and hypercortisolemia, the main hypothesis w...

ea0016oc1.2 | Neuroendocrinology and pituitary | ECE2008

The adequacy of thyroxine replacement in hypopituitary patients

Filipsson Helena , Feldt-Rasmussen Ulla , Kourides Ione , Popovic Vera , Koltowska-Haggstrom Maria , Jonsson Bjorn , Johannsson Gudmundur

Background: Hypopituitary patients with untreated growth hormone deficiency (GHD) have increased fat mass, dyslipidaemia and insulin resistance. Inappropriately low thyroxine doses in patients with central hypothyroidism (CH) may also promote such clinical features.Objective: To examine metabolic outcome of thyroxine replacement in hypopituitary patients before and after GH replacement.Method: One thousand and six hundred and two p...

ea0014oc8.6 | Neuroendocrinology clinical | ECE2007

Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet

Skrtic Stanko , Lennernäs Hans , Nilsson Anna , Bergthorsdottir Ragnhildur , Hedner Thomas , Johannsson Gudmundur

Background: Mortality rate in patients with primary and secondary adrenal insufficiency is increased. A contributing factor could be the dose and the pattern of glucocorticoid replacement therapy. Hydrocortisone administered twice or thrice daily produces high serum peaks and low trough values in-between. A novel, once daily, hydrocortisone modified release tablet with combined immediate and extended release characteristics was developed.Purpose: The aim...

ea0014oc12.5 | Diabetes | ECE2007

The influence of concomitant diabetes mellitus on mortality in Addison’s disease

Bergthorsdottir Ragnhildur , Leonsson-Zachrisson Maria , Odén Anders , Johannsson Gudmundur

Background: The prevalence of type 1 diabetes mellitus (DM) among patients with primary adrenal insufficiency (Addison’s disease) is 3-4 times higher than the expected prevalence in the population. The mortality rate due to DM is more than 3-fold the mortality rate in the background population. The impact of DM on mortality rate in patients with Addison’s disease is not known.Objectives: To study the frequency of DM and its impact on mortality ...